We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Director Marks Says CBER Faces ‘High Turnover’ Amid Ongoing Pandemic Work
Director Marks Says CBER Faces ‘High Turnover’ Amid Ongoing Pandemic Work
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research (CBER), said his center continues to experience large losses of staff during the pandemic — possibly limiting CBER’s ability to achieve its goals for next year.